Citadel Advisors
AQST icon

Citadel Advisors’s Aquestive Therapeutics AQST Stock Holding History

Citadel Advisors’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.35M Sell
565,203
-5,742
-1% -$23.3K ﹤0.01% 5751
2025
Q4 		$3.69M Sell
570,945
-197,505
-26% -$1.23M ﹤0.01% 4800
2025
Q3 		$4.3M Buy
768,450
+616,294
+405% +$2.66M ﹤0.01% 4632
2025
Q2 		$504K Sell
152,156
-307,394
-67% -$882K ﹤0.01% 8611
2025
Q1 		$1.33M Buy
459,550
+77,872
+20% +$236K ﹤0.01% 6321
2024
Q4 		$1.36M Sell
381,678
-490,155
-56% -$2.26M ﹤0.01% 6421
2024
Q3 		$4.34M Buy
871,833
+704,020
+420% +$2.74M ﹤0.01% 4175
2024
Q2 		$436K Sell
167,813
-56,460
-25% -$189K ﹤0.01% 8332
2024
Q1 		$955K Buy
224,273
+56,456
+34% +$188K ﹤0.01% 7008
2023
Q4 		$339K Buy
167,817
+165,112
+6,104% +$292K ﹤0.01% 8921
2023
Q3 		$4.14K Sell
2,705
-582
-18% -$1K ﹤0.01% 13513
2023
Q2 		$5.42K Buy
+3,287
New +$5.95K ﹤0.01% 13501
2023
Q1 		– Sell
-2,910
Closed -$2.52K – 14672
2022
Q4 		$2.63K Sell
2,910
-15,153
-84% -$14.2K ﹤0.01% 14306
2022
Q3 		$21K Sell
18,063
-53,932
-75% -$61K ﹤0.01% 12052
2022
Q2 		$46K Buy
71,995
+35,205
+96% +$46.8K ﹤0.01% 11981
2022
Q1 		$96K Sell
36,790
-61,078
-62% -$178K ﹤0.01% 12324
2021
Q4 		$381K Buy
97,868
+56,157
+135% +$282K ﹤0.01% 10347
2021
Q3 		$182K Buy
+41,711
New +$164K ﹤0.01% 12112
2021
Q2 		– Sell
-75,463
Closed -$301K – 13614
2021
Q1 		$392K Buy
75,463
+51,209
+211% +$272K ﹤0.01% 10226
2020
Q4 		$130K Sell
24,254
-31,738
-57% -$190K ﹤0.01% 10037
2020
Q3 		$272K Buy
55,992
+29,765
+113% +$195K ﹤0.01% 8294
2020
Q2 		$127K Buy
26,227
+15,605
+147% +$71.8K ﹤0.01% 8856
2020
Q1 		$23K Buy
+10,622
New +$40.4K ﹤0.01% 9260
2018
Q4 		– Sell
-25,780
Closed -$451K – 9051
2018
Q3 		$451K Buy
+25,780
New +$425K ﹤0.01% 6861

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors's AQST Position: Q1 2026 in Review

Citadel Advisors reduced its Aquestive Therapeutics (AQST) stake by 1% in Q1 2026, selling an estimated $23.3K and leaving 565,203 shares worth $2.35M. The position accounts for ﹤0.01% of the portfolio, ranked #5751.

Citadel Advisors first reported a position in AQST in Q3 2018 and has held it in 24 quarters since. The position peaked at $4.34M in Q3 2024. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Citadel Advisors held 565,203 shares of Aquestive Therapeutics worth $2.35M as of Q1 2026.
  • Citadel Advisors sold 5,742 Aquestive Therapeutics shares in Q1 2026, an estimated $23.3K.
  • Aquestive Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5751 holding.
  • Citadel Advisors first reported a position in Aquestive Therapeutics in Q3 2018 and has held it in 24 quarters since.
  • Citadel Advisors's Aquestive Therapeutics position peaked at $4.34M in Q3 2024.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.